(IQ Solutions, Inc.) While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits.
The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.